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ABSTRACT 
 
Introduction. Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and 
lethal fibrosing interstitial pneumonia. The median survival from the onset of the 
symptoms is 2.8-4.2 years and the 5-year survival rate is 20%. Its poor 
prognosis, combined with the scarcity of treatment options, provides a strong 
rationale for the development of novel therapeutic strategies. During the last 
decade there has been a huge rise in clinical trials with antifibrotic drugs, 
although only pirfenidone has shown a beneficial effect. 
Areas covered. This article reviews the medical literature on the effectiveness 
and safety of pirfenidone in IPF, by means of a PubMed search from 1995 to 
present, completed by some data on file from the manufacturer. 
Expert opinion. Pirfenidone is the only antifibrotic drug approved for the 
treatment of IPF. Pirfenidone presents a meaningful clinical effect on reductions 
in the decrease in forced vital capacity (FVC), six minute walk test (6MWT) 
distance and mortality, and it improves  the  progression-free survival in IPF 
patients with mild-moderate disease. Pirfenidone is well tolerated, with the most 
common side-effects being gastrointestinal discomfort and photosensitivity. 
Pirfenidone has a favorable benefit-risk profile and represents a suitable 
treatment option for patients with mild-moderate IPF. 
 
Key words.  Antifibrotic drugs, Idiopathic Pulmonary Fibrosis, Pirfenidone 
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1. INTRODUCTION 
IPF is a chronic, progressive, and lethal fibrosing interstitial pneumonia, limited 
to the lung and associated with the histopathological and/or radiological pattern 
of usual interstitial pneumonia (1). Although its etiology is unknown and the 
pathogenesis only partly understood, our current knowledge suggests that 
damage to the alveolar epithelium is probably an important early event followed 
by an aberrant healing response. The median age at diagnosis is 66 years, with 
a male predominance, and prevalence has been increasing in recent years. The 
incidence of IPF is estimated to be between 4.6 and 7.4 cases / 100000, and 
the prevalence is between 13 cases/100000 for females and 20 cases/100000 
for males (1). IPF is characterized by a progressive decline in pulmonary 
function, which quickly leads to respiratory failure and death, although some 
patients may have episodes of acute respiratory worsening despite previous 
stability. With a median survival from the onset of the symptoms of 2.8-4.2 
years and a 5-year survival rate approaching 20%, IPF is more lethal than many 
malignant diseases. The poor prognosis, combined with the scarcity of 
treatment options, provides a strong rationale for the development of novel 
therapeutic strategies for this disease. During the last decade there has been a 
huge rise in clinical trials with antifibrotic drugs. In phase III randomized clinical 
trials with interferon gamma 1-b, pirfenidone, macitentan, bosentan, 
ambrisentan, warfarin, triple therapy (n-acetylcisteine, glucocorticoids, 
azathitoprine), etanercept and sildenafil, only pirfenidone has shown any 
beneficial effects in patients with IPF (2-4). Several national guidelines on IPF 
diagnosis and treatment from Spain, Germany, Denmark, Sweden, Austria, and 
Ireland, have recently recommended pirfenidone as first-choice therapeutic 
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agent in IPF patients with mild-moderate disease, defined as FVC predicted > 
50% (5-9). The National Institute for Health and Clinical Excellence (NICE) 
recommends pirfenidone as a therapeutic option in IPF patients with FVC 
predicted between 50 and 80%. (10).   
 
2. OVERVIEW OF THE MARKET 
Pirfenidone is the only pharmacological agent approved for the treatment of 
mild-moderate IPF (11). Nowadays, there is no drug available for the treatment 
of patients with IPF with advanced disease. 
 
3. INTRODUCTION TO PIRFENIDONE 
Pirfenidone is a pleiotropic molecule with antifibrotic, anti-inflammatory and 
antioxidant effects (12). The antioxidant effect occurs through its ability to 
scavenge reactive oxygen species (13). Studies in animal models of pulmonary 
fibrosis have shown that pirfenidone attenuates a range of inflammatory and 
profibrotic molecules while downregulating histological markers of fibrosis and 
cellular proliferation (14). Pirfenidone inhibits the expression of transforming 
growth factor (TGF)-β and the tissue inhibitor of metalloproteinase-1 (TIMP-1), 
and blocks the proliferative effects of platelet-derived growth factor (PDGF). 
Furthermore, pirfenidone inhibits the release of proinflammatory cytokines such 
as, tumor necrosis factor (TNF)-α , interleukin (IL-1)-β, IL-6, IL-8 and IL-12, as 
well increasing the expression of the anti-inflammatory cytokine IL-10, 
attenuating the release of chemotactic cytokines and reducing the accumulation 
of inflammatory cells in response to different stimuli (14-19) 
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In addition to the modulation of mediators in animal models, cell-based assays 
have demonstrated that pirfenidone inhibits the expression of heat shock 
protein (HSP) 47 in cultured normal lung fibroblasts stimulated with TGF-β-1; it 
was also able to inhibit the expression of collagen in fibroblasts isolated from 
IPF patients (20, 21). Moreover, pirfenidone inhibits the overexpression of 
collagen type I and HSP47 in the alveolar epithelial cell line (A549 cells), (22).  
 
3.1 CHEMISTRY 
Pirfenidone is an orally bioavailable synthetic molecule. Pirfenidone is a 
heterocyclic pyridine (5-methyl-1-phenyl-2-[1H]-pyridine) with a molecular 
weight of 185.22. Pyridines are derived from coal combustion, and can be 
synthesized from aldehyde and ammonia. They are highly soluble in 
dimethylsulfoxide, twice in water and chloroform, and in alcohol. In aqueous 
solution the maximum possible concentration is 2%. (23). 
 
3.2 PHARMACOKINETICS AND METABOLISM 
Oral pirfenidone has linear pharmacokinetics over the dose range of 200-600 
mg. (24). After a single dose of pirfenidone with food at the recommended 
maintenance dose of 801 mg, the mean maximum plasma concentration (Cmax) 
is 7.9 mg/L in healthy adults. Absorption occurs quickly, the time to maximun 
(Tmax) values  being achieve in 30-60 min (25). Median time to Cmax is 3.5 h. 
However, the Cmax is significantly lower when the drug is administered in the fed 
versus fasting states (26). It has been shown that healthy volunteers who 
received pirfenidone with food had a lower incidence of gastrointestinal adverse 
events, than those who received pirfenidone without food. In clinical trials, at 
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concentrations of 1-1000 mg/L, 50-58% of pirfenidone bound to plasma 
proteins, predominantly albumin (27). Pirfenidone is predominantly metabolized 
by the cytochrome (CYP) P450 CYP1A2 enzyme, although other CYP 
enzymes, including CYP2C9, 2C19, 2D6, and 2E, also contribute to the 
metabolism. The major metabolite of pirfenidone is 5-carboxy-pirfenidone which 
is inactive. After a single 801 mg dose, the terminal elimination half life was 2.9 
h (without food) and 2.4 h (with food). No significant gender differences were 
noted for the pharmacokinetic variables (26). Eighty percent of the administered 
dose was excreted in the urine primarily as 5-carboxy-pirfenidone and less than 
1% of the dose recovered in the urine was unaltered, after 6 h of administration. 
Pirfenidone bioavailability is increased by a mean of 60% in patients with 
moderate hepatic function impairment. No clinical relevant changes have been 
observed in pharmacokinetics in patients with mild to severe renal  function 
impairment. However, the drug is contraindicated in patients with severe renal 
impairment (creatinine clearance of < 30 mL/min) or end stage renal disease 
requiring dialysis. (28) 
Pirfenidone may interact with drugs that inhibit CYP1A2, particularly 
fluvoxamine, ciprofloxacin, and propafenone. Consumption of grapefruit also 
inhibits CYP1A2. Concomitant treatment with inhibitors of other CYP 
isoenzymes involved in the metabolism of pirfenidone (fluconazole, 
chloramfenicol, fluoxetine, paroxetine, amiodarone) may interact with 
pirfenidone. Pirfenidone can also interact with CYP1A2, inducers, such as 
tobacco smoke and omeprazole (27) (Table 1). 
 
4. CLINICAL EFFICACY 
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4.1 Clinical trials 
In a prospective, open-label phase II study, pirfenidone was evaluated for its 
tolerability and usefulness in patients with advanced IPF, progressive disease 
and lack of response to conventional therapy (prednisone with or without 
immunosuppressives). Fifty-four patients were followed for mortality, changes in 
lung function and adverse effects. Patients whose lung function had deteriorate 
before enrolement appeared to stabilize after beginning treatment. Patients with 
higher single-breath diffusing capacity for carbon monoxide (DLco ) (> 30% 
predicted) at entry had longer survival.  The adverse effects were minor (29). 
The first large-scale trial of pirfenidone was a Japanese multicenter randomized 
placebo-controlled phase II study of 107 subjects who received either 
pirfenidone 600 mg three times daily (n = 72) or placebo (n = 35). The trial was 
designed to run for 1 year. Although there was a significant decrease in the 
decline of FVC in the pirfenidone group, 9-month interim results showed that 
five subjects from the placebo group had suffered acute exacerbation of the 
disease compared to none in the pirfenidone group, and the study was halted 
(30). 
A phase III clinical trial conducted over 52 weeks was also developed in Japan. 
A total of 275 patients were randomized to either high-dose (1800 mg/day) or 
low-dose (1200 mg/day) pirfenidone or placebo the ratio of 2:1:2. Significant 
differences were observed in vital capacity (VC) decline (primary end-point) 
between the placebo group and the high-dose group and improved progression-
free survival time was seen in the high-dose group. (31). To find out which 
patients specifically benefit from pirfenidone, an additional exploratory analysis 
was performed with the data of this trial. Significant efficacy of pirfenidone in 
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reducing the decline in VC was seen in a subpopulation with %VC ≥ 70% and 
oxygen saturation at baseline (SpO2) < 90%. These are mutually conflicting 
characteristics. According to the author opinion, the desaturation exhibited by 
the subgroup with the better-perserved lung function may have been due to the 
develipment of fibrosis with inflammatory edema and not to established fibrosis. 
In this subpopulation, pirfenidone also suppressed cough and dyspnea (32).  
Recently, marginal decline in FVC (5%) has been reported as being associated 
with poor outcome in IPF. In the same clinical trial, Taniguchi et al sought to 
evaluate the efficacy of pirfenidone from the aspects of 5% changes in VC. 
When 5% change in VC was used as an index instead of the 10% change, the 
efficacy of pirfenidone could be evaluated with higher sensitivity over the 12 
months study. (33).  
The CAPACITY phase III trials consisted of two concurrent multinational 
randomized  double-blind placebo-controlled phase III trials (004 and 006) 
conducted over 72 weeks and designed to evaluate the safety and efficacy of 
pirfenidone in patients with mild-moderate disease (34, 35). In trial 004, 174 
patients were assigned to high-dose pirfenidona (2403 mg/day), 87 to low dose 
(1197 mg/day) and 174 to placebo. In study 006, 171 patients were assigned to 
high-dose pirfenidone (2403 mg/day), and 173 to placebo. In study 004, the 
higher dose of pirfenidone met the primary endpoint, decreasing the decline in 
FVC. In contrast, trial 006 failed to show a significant reduction in FVC, although 
there was a reduced decline in distance walked in the 6MWT (secondary end-
point). The differences observed between the two studies in the effect of 
pirfenidone may be explained by the fact that the subjects in the 006 placebo 
group had a slower rate of decline compared to those in 004. When 004 and 
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006 study data were pooled, pirfenidone shows meaningful clinical effects on 
FVC % predicted (decrease in the decline by 30%), progression free survival 
and 6MWT distance at the dose of 2403 mg/day.. Although these trials were not 
powered to detect an effect on mortality, IPF-related mortality was reduced by 
28%. A Cochrane review encompassing the two Japanese trials and the 
CAPACITY studies, has demonstrated that pirfenidone improves progression-
free survival by 30%. (36).  
The RECAP study is an ongoing open-label extension study evaluating the 
long-term administration of pirfenidone in patients who completed phase III 
CAPACITY program. Preliminary results in 178 patients show that FVC and 
survival outcomes in patients newly treated with pirfenidone in the RECAP 
study were similar to those treated in the CAPACITY trials. These data provide 
further evidence to support the beneficial effect of pirfenidone in IPF (37). A 
phase III study comparing pirfenidone with placebo in patients with mild-to-
moderate IPF is currently under way in the US (ASCEND trial, NCT01366299). 
The PANORAMA study (A Randomized, Double-Blind, Placebo-Controlled, 
Phase II Study of the Safety and Tolerability of N–Acetylcysteine in Patients 
with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenidone, 
EUDRACT 2012-000564-14) is also ongoing.  
 
4.2 Posology and method of administration  
Pirfenidone is indicated in adults for the treatment of mild-to-moderate IPF (FVC 
> 50% predicted (5-9). The National Institute for Health and Clinical Excellence 
recommends pirfenidone in patients with FVC between 50% and 80% predicted 
(10). The approved dose is 2403 mg/day. Each capsule contains 267 mg. Upon 
Page 9 of 58
URL: http://mc.manuscriptcentral.com/eoop  Email: Amina.AbdelLatif@informa.com
Expert Opinion On Pharmacotherapy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 10
initiating treatment, the dose should be titrated to the recommended daily dose 
over a 14-day period: days 1 to 7, one capsule three times a day (801 mg/day); 
days 8 to 14, two capsules, three times a day (1602 mg/day) and day 15 
onward, three capsules, three times a day (2403 mg/day). The drug should be 
taken with food to reduce the possibility of gastrointestinal adverse events and 
dizziness (27). The recommended treatment duration is at least 12 months. If 
there is improvement or stabilization of the disease, the treatment should be 
continued. In case of deterioration, the advisability of continuing treatment or 
instigating other therapeutic strategies should be considered for each patient. 
However, it is recommended that treatment should be discontinued if there is 
evidence of disease progression, that is, a decline in per cent predicted FVC of 
10% or more within any 12 month period (5, 10). 
 
4.3 Post marketing studies 
Open-label studies have been developed, to confirm the efficacy, safety and 
tolerability of pirfenidone and to optimize its indications.  
A European Named Patient Program (NPP) was established by Intermune® to 
make pirfenidone accessible to patients with IPF during the period between the 
authorization of the drug and its availability upon prescription. The results of this 
program have not yet been published. The PASSPORT study (Post-
Authorisation Safety Study of Esbriet® (Pirfenidone): A Prospective 
Observational Registry to Evaluate Long-Term Safety in a Real-World Setting) 
is also ongoing; its objective is to evaluate the long-term safety of pirfenidone. 
In a retrospective study, Okuda et al (38) have described the effects of 
pirfenidone, at the dose of 1800 mg/day during 6 months, in 76 patients with 
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mild-to-severe IPF. Pirfenidone tended to attenuate the degree of decline in 
FVC, particularly in the subgroup of patients with FVC < 60% and showed 
greater efficacy in patients with decline in FVC > 150 ml during the 6-months 
period before the start of therapy. Thus, the degree of disease progression prior 
to the initiation of therapy had an impact on the response to pirfenidone. The 
most frequent adverse effects were anorexia (42%), increase in gamma 
glutamyl transpeptidase (22%), fatigue (14%) and photosensitivity (18%). All the 
reported adverse effects were, howevver, mild, reversible and left no sequelae. 
Moreover, Bonella et al. (39), have reported data on the safety and efficacy of 
pirfenidone (2403 mg/ day) in 45 patients with mild-moderate IPF (mean 
duration of treatment 48 weeks). Sixteen patients (35%) received pirfenidone as 
monotherapy and 29 (65%) in combination with corticosteroids and /or N-
acetylcisteine. The course of the disease was stable during treatment with 
pirfenidone in two out of every three patients. Twenty-six patients (58%) 
suffered from side effects, mostly gastrointestinal, but pirfenidone was 
discontinued because of side effects in only six patients. The results of this 
study confirm the efficacy and safety of pirfenidone in the treatment of IPF. 
Iwasawa et al. (40) investigated the usefulness of high resolution CT scan 
(HRCT) in the imaging assessment of the response to pirfenidone therapy. 
Seventy-eight patients (38 treated with pirfenidone and 40 matched controls) 
were given HRCT on two occasions, with a one-year interval in between. A 
significantly larger proportion of patients treated with pirfenidone showed more 
stable pulmonary function parameters than the controls (65.6% vs 37.5%). The 
decline in VC correlated with the increase in fibrotic lesions in CT scan. These 
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results suggest that CT scan may be useful for evaluating the pirfenidone-
induced slowing progression of pulmonary fibrosis.  
 
5. SAFETY AND TOLERABILITY 
Jiang et al (41) have reported the results of a meta-analysis to analyze the 
safety profile of pirfenidone for treating pulmonary fibrosis. Six-randomized 
controlled trials were analyzed.  A total of 1073 patients were enrolled, 561 in 
the pirfenidone group, and 512 in the placebo group. Four trials assessed the 
treatment of IPF and the remaining two studies, assessed the treatment of 
Hermansky–Pudlak syndrome (30, 31, 34, 42, 43). The combined results of the 
six trials revealed that the pirfenidone group had a significantly higher rate of 
gastrointestinal, neurological and dermatological adverse events. However, 
adverse effects were generally mild or moderate in severity and without any 
clinically significant consequences. Most of the adverse effects disappeared 
with a decrease in the dose or temporary discontinuation of medication.   
The most commonly reported (≥10%) adverse reactions during treatment with 
pirfenidone at a dose of 2403 mg/ day are nausea, rash, fatigue, diarrhea, 
dyspepsia and photosensitivity reaction (table 2). Less frequent adverse effects 
are anorexia, insomnia, hot flush and alteration in the hepatic enzymes alanin 
and aspartate aminotransferases, and gamma glutamyl transferase. (27).  
Gastrointestinal events are less frequent if the drug is administered with food.  
Patients with photosensitivity reaction or rash should use protective sun 
creams, to wear clothing that protects against sun exposure and avoid direct 
sunlight. In case of adverse events, the dose of pirfenidone should be adjusted 
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or the treatment discontinued, according to the established recommendations. 
There are no data on the use of pirfenidone during pregnacy. (27). 
Pirfenidone is contraindicated in case of hypersensitivity to the drug or to any of 
its excipients, concomitant use of fluvoxamine, severe hepatic impairment or 
end-stage liver disease or severe renal impairment or end-stage renal disease 
requiring dialysis. Pirfenidone should be used with caution in patients treated 
with inhibitors or inducers of CYP1A2 (table 1) (27). 
 
6. REGULATORY AFFAIRS 
Pifenidone is an orally administered pyridine that was granted orphan drug 
approval in the European Union for the treatment of mild-to-moderate IPF in 
2011 and it is the only pharmacological agent available for this indication (44). 
In Europe, it is marketed under the brand name Esbriet ® by Intermune Inc. In 
Japan, pirfenidone has been approved for marketing since 2008 under the 
brand name Pirespa® by Shionogi & Co. In 2010, the Food and Drug 
Administration (FDA) denied approval for pirfenidone. A new drug application to 
the FDA is expected depending on the results of the ongoing phase III trial 
ASCEND (Efficacy and safety of Pirfenidone in Patients with Idiopathic 
Pulmonary Fibrosis). 
 
7. CONCLUSION  
IPF is a chronic, progressive, and lethal fibrosing interstitial pneumonia. Its poor 
prognosis, combined with the scarcity of treatment options, provides a strong 
rationale for the development of novel therapeutic strategies for this disease.  
During the last decade several clinical trials with antifibrotic drugs have been 
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developed, although only pirfenidone has shown a beneficial effect. Recent 
national guidelines and the National Institute for Health and Clinical Excellence 
recommend pirfenidone as first-choice therapeutic agent in IPF patients with 
mild-moderate disease, defined as FVC > 50% of predicted. Pirfenidone´s 
adverse-effect profile is acceptable in a disease as severe as IPF. Nowadays, 
pirfenidone is the only pharmacological agent approved for the treatment of 
mild-moderate IPF. 
 
8. EXPERT OPINION 
IPF is a progressively fibrotic disease with a median survival from the onset of 
the symptoms of 2.8 to 4.2 years. The search for effective treatment has 
involved numerous clinical trials with potentially antifibrotic drugs, although only 
pirfenidone has shown any beneficial effect. Four key clinical trials have 
endorsed the efficacy and tolerability of pirfenidone. Pirfenidone has shown 
clinically meaningful effects on decreases in the decline of % FVC, 6MWT 
distance and mortality, as well as on improvements in progression-free survival. 
In addition, pirfenidone could prevent symptoms related to disease progression, 
decrease dependency on oxygen, increase survival and reduce hospitalizations. 
Pirfenidone is well tolerated, with the most common side-effects being 
gastrointestinal discomfort and photosensitivity. Open-label and placebo-
controlled studies are underway to confirm the efficacy and long-term effects of 
pirfenidone. Recently published national guidelines recommend pirfenidone as 
a first-choice therapeutic agent in IPF patients with mild-moderate disease. 
Pirfenidone has a favorable benefit-risk profile and represents a suitable 
treatment option for IPF. 
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9. DRUG SUMMARY BOX 
 
Drug name         Pirfenidone 
Phase             Marketed 
Indication          mild-moderate idiopathic pulmonary fibrosis 
Pharmacology description        antifibrotic, anti-inflammatory, antioxidant  
Route of administration            oral 
Chemical structure  
 
 
 
 
 
Pivotal trials         (30, 31, 34) 
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Table 1.- Pirfenidone. Most commonly reported adverse reactions (> 10% 
patients)* 
 
 
Adverse event Pirfenidone  2403 mg/ day Placebo 
Nausea 32.8** 13.3 
Rash 28.7 8.6 
Fatigue 22.3 13.3 
Diarrhea 21.7 13.5 
Dyspepsia 16.8 5.5 
Photosensitivity 12.2 1.7 
 
* Data from clinical studies including 1345 healthy volunteers and patients (27). 
** % of patients 
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Table 2.- Potential drug interactions of pirfenidone 
 
CYP1A2 inhibitors 
 Fluvoxamine 
 Ciprofloxacin 
 Propafenone 
 Grapefruit juice 
CYP2C9 inhibitors 
 Amiodarone 
 Fluconazole 
 Voriconazole 
CYP2C19 inhibitors 
 Chloramphenicol 
CYP2D6 inhibitors 
 Fluoxetine 
 Paroxetine 
 Quinidine 
CYP1A2 inducers 
 Tobacco smoke 
 Omeprazole 
  
 
 
Abbreviations:   CYP, Cytochrome 
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ABBREVIATIONS 
DLco  single-breath diffusing capacity for carbon monoxide  
FVC  Forced vital capacity 
HRCT  High resolution CT scan 
IPF  Idiopathic pulmonary fibrosis 
VC  Vital capacity 
6MWT Six- minute walk test 
Page 26 of 58
URL: http://mc.manuscriptcentral.com/eoop  Email: Amina.AbdelLatif@informa.com
Expert Opinion On Pharmacotherapy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
Table 1.- Pirfenidone. Most commonly reported adverse reactions (> 10% 
patients)* 
 
 
Adverse event Pirfenidone  2403 mg/ day Placebo 
Nausea 32.8** 13.3 
Rash 28.7 8.6 
Fatigue 22.3 13.3 
Diarrhea 21.7 13.5 
Dyspepsia 16.8 5.5 
Photosensitivity 12.2 1.7 
 
* Data from clinical studies including 1345 healthy volunteers and patients (27). 
** % of patients 
 
 
Page 27 of 58
URL: http://mc.manuscriptcentral.com/eoop  Email: Amina.AbdelLatif@informa.com
Expert Opinion On Pharmacotherapy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
Table 2.- Potential drug interactions of pirfenidone 
 
CYP1A2 inhibitors 
 Fluvoxamine 
 Ciprofloxacin 
 Propafenone 
 Grapefruit juice 
CYP2C9 inhibitors 
 Amiodarone 
 Fluconazole 
 Voriconazole 
CYP2C19 inhibitors 
 Chloramphenicol 
CYP2D6 inhibitors 
 Fluoxetine 
 Paroxetine 
 Quinidine 
CYP1A2 inducers 
 Tobacco smoke 
 Omeprazole 
  
 
 
Abbreviations:   CYP, Cytochrome 
 
Page 28 of 58
URL: http://mc.manuscriptcentral.com/eoop  Email: Amina.AbdelLatif@informa.com
Expert Opinion On Pharmacotherapy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
Declaration of interest: 
Author 1 declares that he has received funding for given lectures at educational events and/or for 
scientific advice and / or research from Intermune, Actelion and Boehringer Ingelheim in relation to 
the subject of the manuscript. 
 
Author 2: Intermune. 
Author 3: Intermune, Zambon, Boehringer Ingelheim.  
Page 29 of 58
URL: http://mc.manuscriptcentral.com/eoop  Email: Amina.AbdelLatif@informa.com
Expert Opinion On Pharmacotherapy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 1 
 
 
 
 
 
 
 
PIRFENIDONE FOR THE TREATMENT OF IDIOPATHIC PULMONARY 
FIBROSIS 
 
 
Page 30 of 58
URL: http://mc.manuscriptcentral.com/eoop  Email: Amina.AbdelLatif@informa.com
Expert Opinion On Pharmacotherapy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 2 
 
Antoni Xaubet, MD, PhD (corresponding author) 
Servei de Pneumologia. Hospital Clínic. Barcelona. Universitat de Barcelona 
Centro de Investigaciones Médicas en Red de Enfermedades Respiratorias 
(CIBERES) 
Servei de Pneumologia. Hospital Clinic. Villarroel 170. Barcelona 08036. Spain 
Phone  60044756 
FAX 34932275455 
e-mail: axaubet@clinic.ub.es 
 
Anna Serrano Mollar, PhD 
Institut d´Investigacions Biomèdiques de Barcelona. Consejo Superior de 
Investgaciones Científicas. Barcelona. Centro de Investigaciones Médicas en 
Red de Enfermedades Respiratorias (CIBERES). 
  
Julio Ancochea, MD, PhD 
Servicio de Neumología. Hospital Universitario de La Princesa. Madrid 
Page 31 of 58
URL: http://mc.manuscriptcentral.com/eoop  Email: Amina.AbdelLatif@informa.com
Expert Opinion On Pharmacotherapy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 3 
ABSTRACT 
 
Introduction. Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and 
lethal fibrosing interstitial pneumonia. The median survival from the onset of the 
symptoms is 2.8-4.2 years and the 5-year survival rate is 20%. Its poor 
prognosis, combined with the scarcity of treatment options, provides a strong 
rationale for the development of novel therapeutic strategies. During the last 
decade there has been a huge rise in clinical trials with antifibrotic drugs, 
although only pirfenidone (Esbriet) has shown a beneficial effect. 
Areas covered. This article reviews the medical literature on the effectiveness 
and safety of pirfenidone in IPF, by means of a PubMed search from 1995 to 
present, completed by some data on file from the manufacturer. 
Expert opinion. Pirfenidone is the only antifibrotic drug approved for the 
treatment of IPF. Pirfenidone presents a meaningful clinical effect on reductions 
in the decrease in forced vital capacity (FVC), six minute walk test (6MWT) 
distance and mortality, and it improves  the  progression-free survival in IPF 
patients with mild-moderate disease. Pirfenidone is well tolerated, with the most 
common side-effects being gastrointestinal discomfort and photosensitivity. 
Pirfenidone has a favorable benefit-risk profile and represents a suitable 
treatment option for patients with mild-moderate IPF. 
 
Key words.  Antifibrotic drugs, Idiopathic Pulmonary Fibrosis, Pirfenidone 
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1. INTRODUCTION 
IPF is a chronic, progressive, and lethal fibrosing interstitial pneumonia, limited 
to the lung and associated with the histopathological and/or radiological pattern 
of usual interstitial pneumonia (1). Although its etiology is unknown and the 
pathogenesis only partly understood, our current knowledge suggests that 
damage to the alveolar epithelium is probably an important early event followed 
by an aberrant healing response. The median age at diagnosis is 66 years, with 
a male predominance, and prevalence has been increasing in recent years. The 
incidence of IPF is estimated to be between 4.6 and 7.4 cases/100,000, and the 
prevalence is between 13 cases/100,000 for females and 20 cases/100,000 for 
males (1). IPF is characterized by a progressive decline in pulmonary function, 
which quickly leads to respiratory failure and death, although some patients 
may have episodes of acute respiratory worsening despite previous stability. 
With a median survival from the onset of the symptoms of 2.8-4.2 years and a 
5-year survival rate approaching 20%, IPF is more lethal than many malignant 
diseases. The poor prognosis, combined with the scarcity of treatment options, 
provides a strong rationale for the development of novel therapeutic strategies 
for this disease. During the last decade there has been a huge rise in clinical 
trials with antifibrotic drugs. In phase III randomized clinical trials with interferon 
gamma 1-b, pirfenidone, macitentan, bosentan, ambrisentan, warfarin, triple 
therapy (n-acetylcisteine, glucocorticoids, azathitoprine), etanercept and 
sildenafil, only pirfenidone (Esbriet) has shown any beneficial effects in patients 
with IPF (2-4). Several national guidelines on IPF diagnosis and treatment from 
Spain, Germany, Denmark, Sweden, Austria, and Ireland, have recently 
recommended pirfenidone as first-choice therapeutic agent in IPF patients with 
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mild-moderate disease, defined as FVC predicted > 50% (5-9). In some other 
European countries, such as Italy, pirfenidone is however, already commercially 
available. The National Institute for Health and Clinical Excellence (NICE) 
recommends pirfenidone as a therapeutic option in IPF patients with FVC 
predicted between 50 and 80% (10).   
 
2. OVERVIEW OF THE MARKET 
Pirfenidone is the only pharmacological agent approved for the treatment of 
mild-moderate IPF (11). Nowadays, there is no drug available for the treatment 
of patients with IPF in an advance stage. 
 
3. INTRODUCTION TO PIRFENIDONE 
Studies performed in animal models of pulmonary fibrosis and in human 
pulmonary cell-based assays have demonstrated that pirfenidone is a 
pleiotropic molecule with antifibrotic, anti-inflammatory and antioxidant effects 
(12). The antioxidant effect occurs through its ability to scavenge reactive 
oxygen species in vitro (13). Studies in animal models of pulmonary fibrosis 
have shown that pirfenidone attenuates a range of inflammatory and profibrotic 
molecules while down-regulating histological markers of fibrosis and cellular 
proliferation (14). Pirfenidone inhibits the expression of transforming growth 
factor (TGF)-β and the tissue inhibitor of metalloproteinase-1 (TIMP-1), and 
blocks the proliferative effects of platelet-derived growth factor (PDGF). 
Furthermore, pirfenidone inhibits the release of proinflammatory cytokines such 
as, tumor necrosis factor (TNF)-α , interleukin (IL-1)-β, IL-6, IL-8 and IL-12, as 
well as increasing the expression of the anti-inflammatory cytokine IL-10, 
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attenuating the release of chemotactic cytokines and reducing the accumulation 
of inflammatory cells in response to different stimuli (14-19). 
In addition to the modulation of mediators in animal models, cell-based assays 
have demonstrated that pirfenidone inhibits the expression of heat shock 
protein (HSP) 47 in cultured normal lung fibroblasts stimulated with TGF-β-1; it 
was also able to inhibit the expression of collagen in fibroblasts isolated from 
IPF patients (20, 21). Moreover, pirfenidone inhibits the overexpression of 
collagen type I and HSP47 in the alveolar epithelial cell line (A549 cells) (22).  
 
3.1 CHEMISTRY 
Pirfenidone is an orally bioavailable synthetic molecule. Pirfenidone is a 
heterocyclic pyridine (5-methyl-1-phenyl-2-[1H]-pyridine) with a molecular 
weight of 185.22. Pyridines are derived from coal combustion, and can be 
synthesized from aldehyde and ammonia. They are highly soluble in 
dimethylsulfoxide, twice in water and chloroform, and in alcohol. In aqueous 
solution the maximum possible concentration is 2% (23). 
 
3.2 PHARMACOKINETICS AND METABOLISM 
Oral pirfenidone has linear pharmacokinetics over the dose range of 200-600 
mg. (24). After a single dose of pirfenidone with food at the recommended 
maintenance dose of 801 mg, the mean maximum plasma concentration (Cmax) 
is 7.9 mg/L in healthy adults. Absorption occurs quickly, the time to maximum 
(Tmax) values  being achieved in 30-60 min (25). Median time to Cmax is 3.5 h. 
However, the Cmax is significantly lower when the drug is administered in the fed 
versus fasting states (26). Concomitant intake of food reduce by 20% the rate 
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and extent of absorption, which is associated with a better tolerability to 
pirfenidone  It has been shown that healthy volunteers who received pirfenidone 
with food had and a lower incidence of gastrointestinal adverse events, than 
those who received pirfenidone without food. (24). In clinical trials, at 
concentrations of 1-1000 mg/L, 50-58% of pirfenidone bound to plasma 
proteins, predominantly albumin (27). Pirfenidone is predominantly metabolized 
by the cytochrome (CYP) P450 CYP1A2 enzyme, although other CYP 
enzymes, including CYP2C9, 2C19, 2D6, and 2E, also contribute to the 
metabolism. The major metabolite of pirfenidone is 5-carboxy-pirfenidone which 
is inactive. After a single 801 mg dose, the terminal elimination half-life was 2.9 
h (without food) and 2.4 h (with food). No significant gender differences were 
noted for the pharmacokinetic variables (26). Eighty percent of the administered 
dose was excreted in the urine primarily as 5-carboxy-pirfenidone and less than 
1% of the dose recovered in the urine was unaltered, after 6 h of administration. 
Pirfenidone bioavailability is increased by a mean of 60% in patients with 
moderate hepatic function impairment. No clinical relevant changes have been 
observed in pharmacokinetics in patients with mild to severe renal function 
impairment. However, the drug is contraindicated in patients with severe renal 
impairment (creatinine clearance of < 30 mL/min) or end stage renal disease 
requiring dialysis (28). 
Pirfenidone may interact with drugs that inhibit CYP1A2, particularly 
fluvoxamine, ciprofloxacin, and propafenone. Consumption of grapefruit also 
inhibits CYP1A2. Concomitant treatment with inhibitors of other CYP 
isoenzymes involved in the metabolism of pirfenidone (fluconazole, 
chloramfenicol, fluoxetine, paroxetine, amiodarone) may interact with 
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pirfenidone. Pirfenidone can also interact with CYP1A2, inducers, such as 
tobacco smoke and omeprazole (27) (Table 1). 
 
4. CLINICAL EFFICACY 
4.1 Clinical trials 
In a prospective, open-label phase II study, pirfenidone was evaluated for its 
tolerability and usefulness in patients with advanced IPF, progressive disease 
and lack of response to conventional therapy (prednisone with or without 
immunosuppressives). Fifty-four patients were followed for mortality, changes in 
lung function and adverse effects. Patients whose lung function had 
deteriorated before enrolment appeared to stabilize after beginning the 
treatment. Patients with higher single-breath diffusing capacity for carbon 
monoxide (DLco ) (> 30% predicted) at entry had longer survival rates. The 
adverse effects were minor (29). 
The first large-scale trial of pirfenidone was a Japanese multicenter randomized 
placebo-controlled phase II study of 107 subjects who received either 
pirfenidone 600 mg three times daily (n = 72) or placebo (n = 35). The trial was 
designed to run for 1 year. Although there was a significant decrease in the 
decline of FVC in the pirfenidone group, 9-month interim results showed that 
five subjects from the placebo group had suffered acute exacerbation of the 
disease compared to none in the pirfenidone group, and the study was halted 
(30). 
A phase III clinical trial conducted over 52 weeks was also developed in Japan. 
A total of 275 patients were randomized to either high-dose (1800 mg/day) or 
low-dose (1200 mg/day) pirfenidone or placebo at the ratio of 2:1:2. Significant 
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differences were observed in vital capacity (VC) decline (primary end-point) 
between the placebo group and the high-dose group and improved progression-
free survival time was seen in the high-dose group. (31). In order to find out 
which patients specifically benefit from pirfenidone, an additional exploratory 
analysis was performed with the data of this trial. Significant efficacy of 
pirfenidone in reducing the decline in VC was seen in a subpopulation with 
%VC ≥ 70% and oxygen saturation at baseline (SpO2) < 90%. These are 
mutually conflicting characteristics. According to the author’s opinion, the 
desaturation exhibited by the subgroup with the better-preserved lung function 
may have been due to the development of fibrosis with inflammatory edema 
and not to established fibrosis. In this subpopulation, pirfenidone also 
suppressed cough and dyspnea (32).  Recently, marginal decline in FVC (5%) 
has been reported as being associated with poor outcome in IPF. In the same 
clinical trial, Taniguchi et al. sought to e aluate the efficacy of pirfenidone from 
the aspects of 5% changes in VC. When 5% change in VC was used as an 
index instead of the 10% change, the efficacy of pirfenidone could be evaluated 
with higher sensitivity over the 12 months study (33).  
The CAPACITY phase III trials consisted of two concurrent multinational 
randomized  double-blind placebo-controlled phase III trials (004 and 006) 
conducted over 72 weeks and designed to evaluate the safety and efficacy of 
pirfenidone in patients with mild-moderate disease (34, 35). In trial 004, 174 
patients were assigned to high-dose pirfenidone (2403 mg/day), 87 to low dose 
(1197 mg/day) and 174 to placebo. In study 006, 171 patients were assigned to 
high-dose pirfenidone (2403 mg/day), and 173 to placebo. In study 004, the 
higher dose of pirfenidone met the primary endpoint, decreasing the decline in 
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FVC. In contrast, trial 006 failed to show a significant reduction in FVC, although 
there was a reduced decline in distance walked in the 6MWT (secondary end-
point). The differences observed between the two studies in the effect of 
pirfenidone may be explained by the fact that the subjects in the 006 placebo 
group had a slower rate of decline compared to those in 004. When 004 and 
006 study data were pooled, pirfenidone showed meaningful clinical effects on 
FVC % predicted (decrease in the decline by 30%), progression free survival 
and 6MWT distance at the dose of 2403 mg/day. Although these trials were not 
empowered to detect an effect on mortality, IPF-related mortality was reduced 
by 28%. A Cochrane review encompassing the two Japanese trials and the 
CAPACITY studies, has demonstrated that pirfenidone improves progression-
free survival by 30%. (36). However, there are still no data for having longer 
overall survival in patients treated with pirfenidone.  
The RECAP study is an ongoing open-label extension study evaluating the 
long-term administration of pirfenidone in patients who completed phase III 
CAPACITY program. Preliminary results in 178 patients show that FVC and 
survival outcomes in patients newly treated with pirfenidone in the RECAP 
study were similar to those treated in the CAPACITY trials. These data provide 
further evidence to support the beneficial effect of pirfenidone in IPF (37). A 
phase III study comparing pirfenidone with placebo in patients with mild-to-
moderate IPF is currently underway in the US (ASCEND trial, NCT01366299). 
The PANORAMA study (A Randomized, Double-Blind, Placebo-Controlled, 
Phase II Study of the Safety and Tolerability of N–Acetylcysteine in Patients 
with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenidone, 
EUDRACT 2012-000564-14) is also ongoing. The objective of this trial is to 
Page 39 of 58
URL: http://mc.manuscriptcentral.com/eoop  Email: Amina.AbdelLatif@informa.com
Expert Opinion On Pharmacotherapy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 11
assess the safety and tolerability of the treatment with N–Acetylcysteine in 
patients with mild-to-moderate IPF on background treatment of pirfenidone. 
 
4.2 Posology and method of administration  
Pirfenidone is indicated in adults for the treatment of mild-to-moderate IPF (FVC 
> 50% predicted (5-9). The National Institute for Health and Clinical Excellence 
recommends pirfenidone in patients with FVC between 50% and 80% predicted 
(10). The approved dose is 2403 mg/day. Each capsule contains 267 mg. Upon 
initiating treatment, the dose should be titrated to the recommended daily dose 
over a 14-day period: days 1 to 7, one capsule three times a day (801 mg/day); 
days 8 to 14, two capsules, three times a day (1602 mg/day) and day 15 
onward, three capsules, three times a day (2403 mg/day). The drug should be 
taken with food to reduce the possibility of gastrointestinal adverse events and 
dizziness (27). The recommended treatment duration is at least 12 months. If 
there is improvement or stabilization of the disease, the treatment should be 
continued. In case of deterioration, the advisability of continuing treatment or 
instigating other therapeutic strategies should be considered for each patient. 
However, it It is recommended that treatment should be discontinued if there is 
evidence of disease progression, that is, a decline in percentage predicted FVC 
of 10% or more within any 12 month period (5, 10). However, the decision of 
discontinuation should be considered according to the individual benefit and 
adverse effects under the comprehensive evaluation. 
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4.3 Post marketing studies 
Open-label studies have been developed, to confirm the efficacy, safety and 
tolerability of pirfenidone and to optimize its indications.  
A European Named Patient Program (NPP) was established by Intermune to 
make pirfenidone accessible to patients with IPF during the period between the 
authorization of the drug and its availability upon prescription. The results of this 
program have not yet been published. The PASSPORT study (Post-
Authorisation Safety Study of Esbriet® (Pirfenidone): A Prospective 
Observational Registry to Evaluate Long-Term Safety in a Real-World Setting) 
is also ongoing; its objective is to evaluate the long-term safety of pirfenidone. 
In a retrospective study, Okuda et al. (38) have described the effects of 
pirfenidone, at the dose of 1800 mg/day during 6 months, in 76 patients with 
mild-to-severe IPF. Pirfenidone tended to attenuate the degree of decline in 
FVC, particularly in the subgroup of patients with FVC < 60% and showed 
greater efficacy in patients with a decline in FVC > 150 ml during the 6-months 
period before the start of therapy. Thus, the degree of disease progression prior 
to the initiation of therapy had an impact on the response to pirfenidone. The 
most frequent adverse effects were anorexia (42%), increase in gamma 
glutamyl transpeptidase (22%), fatigue (14%) and photosensitivity (18%). All the 
reported adverse effects were, however, mild, reversible and left no sequelae. 
Moreover, Bonella et al. (39), have reported data on the safety and efficacy of 
pirfenidone (2403 mg/ day) in 45 patients with mild-moderate IPF (mean 
duration of treatment 48 weeks). Sixteen patients (35%) received pirfenidone as 
monotherapy and 29 (65%) in combination with corticosteroids and /or N-
acetylcisteine. The course of the disease was stable during treatment with 
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pirfenidone in two out of every three patients. Twenty-six patients (58%) 
suffered from side effects, mostly gastrointestinal, but pirfenidone was 
discontinued because of side effects in only six patients. The results of this 
study confirm the efficacy and safety of pirfenidone in the treatment of IPF. In 
another study, Inoue et al. have reported the efficacy and safety profile of 
pirfenidone in more than 1,300 Japanese patients with IPF. Pirfenidone kept the 
decline in VC to a minimum (mean change – 0.07 L) in patients treated 6 
months o longer. Incidences of decreased appetite, photosensitivity reaction 
and nausea were 29%, 15% and 8.3% respectively, although most of these 
adverse drug reactions were manageable (40). 
Iwasawa et al. (41) investigated the usefulness of high resolution CT scan 
(HRCT) in the imaging assessment of the response to pirfenidone therapy. 
Seventy-eight patients (38 treated with pirfenidone and 40 matched controls) 
were given HRCT on two occasions, with a one-year interval in between. A 
significantly larger proportion of patients treated with pirfenidone showed more 
stable pulmonary function parameters than the controls (65.6% vs 37.5%). The 
decline in VC correlated with the increase in fibrotic lesions in CT scan. These 
results suggest that CT scan may be useful for evaluating the pirfenidone-
induced slowing progression of pulmonary fibrosis.  
 
5. SAFETY AND TOLERABILITY 
Jiang et al (42) have reported the results of a meta-analysis to analyze the 
safety profile of pirfenidone for treating pulmonary fibrosis. Six-randomized 
controlled trials were analyzed.  A total of 1073 patients were enrolled, 561 in 
the pirfenidone group, and 512 in the placebo group. Four trials assessed the 
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treatment of IPF and the remaining two studies, assessed the treatment of 
Hermansky–Pudlak syndrome (30, 31, 34, 43, 44). The combined results of the 
six trials revealed that the pirfenidone group had a significantly higher rate of 
gastrointestinal, neurological and dermatological adverse events. However, 
adverse effects were generally mild or moderate in severity and without any 
clinically significant consequences. Most of the adverse effects disappeared 
with a decrease in the dose or temporary discontinuation of medication.   
The most commonly reported (≥10%) adverse reactions during treatment with 
pirfenidone at a dose of 2403 mg/day are nausea, rash, fatigue, diarrhea, 
dyspepsia and photosensitivity reaction (table 2). Less frequent adverse effects 
are anorexia, insomnia, hot flush and alteration in the hepatic enzymes alanin 
and aspartate aminotransferases, and gamma glutamyl transferase (27).  
Gastrointestinal events are less frequent if the drug is administered with food.  
Patients with photosensitivity reaction or rash should use protective sun 
creams, wear clothing that protects against sun exposure and avoid direct 
sunlight. In case of adverse events, the dose of pirfenidone should be adjusted 
or the treatment discontinued, according to the established recommendations. 
There are no data on the use of pirfenidone during pregnancy (27). 
Pirfenidone is contraindicated in case of hypersensitivity to the drug or to any of 
its excipients, concomitant use of fluvoxamine, severe hepatic impairment or 
end-stage liver disease or severe renal impairment or end-stage renal disease 
requiring dialysis. Pirfenidone should be used with caution in patients treated 
with inhibitors or inducers of CYP1A2 (table 1) (27). 
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6. REGULATORY AFFAIRS 
Pifenidone is an orally administered pyridine that was granted orphan drug 
approval in the European Union for the treatment of mild-to-moderate IPF in 
2011 and it is the only pharmacological agent available for this indication (45). 
In Europe, it is marketed under the brand name Esbriet ® by Intermune Inc. In 
Japan, pirfenidone has been approved for marketing since 2008 under the 
brand name Pirespa® by Shionogi & Co. In 2010, the Food and Drug 
Administration (FDA) denied approval for pirfenidone. A new drug application to 
the FDA is expected depending on the results of the ongoing phase III trial 
ASCEND (Efficacy and safety of Pirfenidone in Patients with Idiopathic 
Pulmonary Fibrosis). 
 
7. CONCLUSION  
IPF is a chronic, progressive, and lethal fibrosing interstitial pneumonia. Its poor 
prognosis, combined with the scarcity of treatment options, provides a strong 
rationale for the development of novel therapeutic strategies for this disease.  
During the last decade several clinical trials with antifibrotic drugs have been 
developed, although only pirfenidone has shown a beneficial effect. Recent 
national guidelines and the National Institute for Health and Clinical Excellence 
recommend pirfenidone as first-choice therapeutic agent in IPF patients with 
mild-moderate disease, defined as FVC > 50% of predicted. Pirfenidone´s 
adverse-effect profile is acceptable in a disease as severe as IPF. Nowadays, 
pirfenidone is the only pharmacological agent approved for the treatment of 
mild-moderate IPF. 
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8. EXPERT OPINION 
IPF is a rare and orphan disease characterized by a progressive lung fibrosis 
with a median survival from the onset of the symptoms of 2.8 to 4.2 years. An 
international consensus statement for the diagnosis and treatment of IPF was 
published in 2011. In this consensus, the diagnostic criteria of IPF were 
redefined and new decisions for diagnosis and clinical management were 
established. However, the committee did not find sufficient evidence to support 
the use of any specific pharmacologic therapy for patients with IPF. Since the 
publication of the 2011 international consensus we have known the final results 
of several clinical trials with antifibrotic drugs, although only pirfenidone has 
shown any beneficial effect. Four key clinical trials have endorsed the efficacy 
and tolerability of pirfenidone. Pirfenidone has shown clinically meaningful 
effects on decreases in the decline of % FVC, 6MWT distance and IPF- related 
mortality, as well as on improvements in progression-free survival. In addition, 
pirfenidone could prevent symptoms related to disease progression, decrease 
dependency on oxygen, and reduce hospitalizations. Moreover, post-marketing 
studies have confirmed these beneficial effects of pirfenidone. Thus, pirfenidone 
seems to have a modest but measurable effect on slowing the progression of 
the disease, but there is uncertainty in whether this benefit will persists over 
time. Therefore, the main goal of long term treatment with pirfenidone is to 
increase the survival. It is an important point because there are still no data for 
having longer overall survival of patients treated with pirfenidone. In this 
context, open-label and placebo-controlled studies are underway to confirm the 
efficacy and safety of pirfenidone. Pirfenidone is well tolerated, with the most 
common side-effects being gastrointestinal discomfort and photosensitivity. It is 
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considered that the pirfenidone´s adverse-effect profile is acceptable in a 
disease as severe as IPF.  
Pirfenidone is the only pharmacological agent approved for the treatment of 
mild-moderate IPF. Recent national guidelines and the National Institute for 
Health and Clinical Excellence recommend pirfenidone as first-choice 
therapeutic agent in IPF patients with mild-moderate disease, defined as FVC > 
50% of predicted. Depending on the results of the ongoing clinical trials, 
pirfenidone will likely become in the next few years in the main treatment for 
mild- moderate IPF. 
Nowadays, there is no drug available for the treatment of patients with IPF with 
advanced disease, which is defined by FVC lower than 50% predicted. To date, 
the majority of clinical trials in IPF have included only patients with mild-
moderate disease. One of the research projects that should be done, is a 
clinical trial of pirfenidone in IPF patients with advanced disease, with the aim of 
evaluating its efficacy in this group of patients.  
 At present, clinical trials are underway with other antifibrotic mediators in 
patients with IPF, but we still do not know the results. In conclusion, pirfenidone 
has a favourable benefit-risk profile and represents a suitable treatment option 
for IPF. 
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9. DRUG SUMMARY BOX 
 
Drug name         Pirfenidone 
Phase             Marketed 
Indication          mild-moderate idiopathic pulmonary fibrosis 
Pharmacology description        antifibrotic, anti-inflammatory, antioxidant  
Route of administration            oral 
Chemical structure  
 
 
 
 
 
Pivotal trials         (30, 31, 34) 
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Table 1.- Pirfenidone. Most commonly reported adverse reactions (> 10% 
patients)* 
 
 
Adverse event Pirfenidone  2403 mg/ day Placebo 
Nausea 32.8** 13.3 
Rash 28.7 8.6 
Fatigue 22.3 13.3 
Diarrhea 21.7 13.5 
Dyspepsia 16.8 5.5 
Photosensitivity 12.2 1.7 
 
* Data from clinical studies including 1,345 healthy volunteers and patients (27). 
** % of patients 
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Table 2.- Potential drug interactions of pirfenidone 
 
CYP1A2 inhibitors 
 Fluvoxamine 
 Ciprofloxacin 
 Propafenone 
 Grapefruit juice 
CYP2C9 inhibitors 
 Amiodarone 
 Fluconazole 
 Voriconazole 
CYP2C19 inhibitors 
 Chloramphenicol 
CYP2D6 inhibitors 
 Fluoxetine 
 Paroxetine 
 Quinidine 
CYP1A2 inducers 
 Tobacco smoke 
 Omeprazole 
  
 
 
Abbreviations:   CYP, Cytochrome 
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ABBREVIATIONS 
 
DLco  single-breath diffusing capacity for carbon monoxide  
FVC  Forced vital capacity 
HRCT  High resolution CT scan 
IPF  Idiopathic pulmonary fibrosis 
VC  Vital capacity 
6MWT Six- minute walk test 
Page 58 of 58
URL: http://mc.manuscriptcentral.com/eoop  Email: Amina.AbdelLatif@informa.com
Expert Opinion On Pharmacotherapy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
